Skip to content

Study · Randomized controlled trial · n = 54 · 2023

4 results

Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.

Desborough MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, Woodhouse LJ, Craig J, Krishnan K, Brennan PM, Dineen RA, Coats TJ, Hepburn T, Bath PM, Sprigg N

The Lancet. Neurology1 Jul 2023Cited by 24 (Europe PMC)

PMID37353276 (opens in a new tab)PMCIDPMC10284719 (opens in a new tab)DOI10.1016/s1474-4422(23)00157-6 (opens in a new tab)PepBankPUB-37353276
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In intracerebral haemorrhage patients taking antiplatelets, death or dependency occurred in 22% with desmopressin versus 37% with placebo at day 90.

    In plain wordsIn brain haemorrhage patients taking antiplatelets, death or dependency occurred less often with desmopressin than placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseDeath or dependency at day 90
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Disability and survival · Nervous system and cognition
    Studied dose
    20 μg · intravenous · single doseAs given in this study (human).

    Measurements

    Death or dependency
    22%
    desmopressin, six of 27
    Death or dependency
    37%
    placebo, ten of 27

    Source sentences

    Summary
    Death or dependency on others for daily activities at day 90 (modified Rankin Scale score >4) occurred in six (22%) of 27 participants in the desmopressin group and ten (37%) of 27 participants in the placebo group.
    3 context sentences
    Summary · context
    DASH was a phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Summary · context
    Patients were recruited from ten acute stroke centres in the UK and were eligible if they had an intracerebral haemorrhage with stroke symptom onset within 24 h of randomisation, were aged 18 years or older, and were taking an antiplatelet drug.
    Summary · context
    Participants were randomly assigned (1:1) to a single dose of intravenous desmopressin 20 μg or matching placebo.
  2. 02HumanRandomized controlled trialSafety outcome

    In intracerebral haemorrhage patients, serious adverse events occurred in 12 participants receiving desmopressin versus 13 receiving placebo.

    In plain wordsIn brain haemorrhage patients, serious adverse events occurred in 44% with desmopressin versus 48% with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseSerious adverse events
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg · intravenous · single doseAs given in this study (human).

    Measurements

    Serious adverse events
    44%
    desmopressin
    Serious adverse events
    48%
    placebo

    Source sentences

    Summary
    Serious adverse events occurred in 12 (44%) participants in the desmopressin group and 13 (48%) participants in the placebo group.
    3 context sentences
    Summary · context
    DASH was a phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Summary · context
    Patients were recruited from ten acute stroke centres in the UK and were eligible if they had an intracerebral haemorrhage with stroke symptom onset within 24 h of randomisation, were aged 18 years or older, and were taking an antiplatelet drug.
    Summary · context
    Participants were randomly assigned (1:1) to a single dose of intravenous desmopressin 20 μg or matching placebo.
  3. 03HumanRandomized controlled trialSafety outcome

    In intracerebral haemorrhage patients, stroke expansion occurred in four of 27 desmopressin recipients versus six of 27 placebo recipients.

    In plain wordsIn brain haemorrhage patients, stroke expansion occurred in 15% with desmopressin versus 22% with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseHaemorrhagic stroke expansion
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    20 μg · intravenous · single doseAs given in this study (human).

    Measurements

    Stroke expansion
    15%
    desmopressin
    Stroke expansion
    22%
    placebo

    Source sentences

    Summary
    The most common adverse events were expansion of the haemorrhagic stroke (four [15%] of 27 participants in the desmopressin group and six [22%] of 27 participants in the placebo group) and pneumonia (one [4%] of 27 participants in the desmopressin group and six [22%] of 27 participants in the placebo group).
    3 context sentences
    Summary · context
    DASH was a phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Summary · context
    Patients were recruited from ten acute stroke centres in the UK and were eligible if they had an intracerebral haemorrhage with stroke symptom onset within 24 h of randomisation, were aged 18 years or older, and were taking an antiplatelet drug.
    Summary · context
    Participants were randomly assigned (1:1) to a single dose of intravenous desmopressin 20 μg or matching placebo.
  4. 04HumanRandomized controlled trialSafety outcome

    In intracerebral haemorrhage patients, pneumonia occurred in one of 27 desmopressin recipients versus six of 27 placebo recipients.

    In plain wordsIn brain haemorrhage patients, pneumonia occurred in 4% with desmopressin versus 22% with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreasePneumonia
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Adverse events · Respiratory
    Studied dose
    20 μg · intravenous · single doseAs given in this study (human).

    Measurements

    Pneumonia
    4%
    desmopressin
    Pneumonia
    22%
    placebo

    Source sentences

    Summary
    The most common adverse events were expansion of the haemorrhagic stroke (four [15%] of 27 participants in the desmopressin group and six [22%] of 27 participants in the placebo group) and pneumonia (one [4%] of 27 participants in the desmopressin group and six [22%] of 27 participants in the placebo group).
    3 context sentences
    Summary · context
    DASH was a phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Summary · context
    Patients were recruited from ten acute stroke centres in the UK and were eligible if they had an intracerebral haemorrhage with stroke symptom onset within 24 h of randomisation, were aged 18 years or older, and were taking an antiplatelet drug.
    Summary · context
    Participants were randomly assigned (1:1) to a single dose of intravenous desmopressin 20 μg or matching placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.